Rohto Pharmaceutical Co (TSE:4527) Cyclically Adjusted Revenue per Share: 円1,060.31 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4527 Rohto Pharmaceutical Co Ltd TSE:4527
83 GF Score
Price 円2,483.50
GF Value 円3,479.27
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Rohto Pharmaceutical Co TSE:4527 -1.62% 83 Cyclically Adjusted Revenue per Share is 円1,060.31 as of Mar. 2026. GuruFocus rates TSE:4527 with a GF Score™ of 83/100 and a GF Value™ of 円3,479.27 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Rohto Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was 円384.592. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円1,060.31 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Rohto Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 8.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Rohto Pharmaceutical Co was 9.50% per year. The lowest was 4.70% per year. And the median was 7.15% per year.

As of today (2026-07-31), Rohto Pharmaceutical Co's current stock price is 円2483.50. Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円1,060.31. Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 2.34.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Rohto Pharmaceutical Co was 4.86. The lowest was 1.94. And the median was 2.49.


Rohto Pharmaceutical Co  (TSE:4527) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2483.50/1060.31
=2.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Rohto Pharmaceutical Co was 4.86. The lowest was 1.94. And the median was 2.49.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Rohto Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 746.98 816.32 887.85 981.06 1,060.31

Rohto Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 981.06 1,004.99 1,022.44 1,047.96 1,060.31

TSE:4527 vs PG, CL, KVUE: Cyclically Adjusted Revenue per Share Comparison

For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rohto Pharmaceutical Co Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


TSE:4527
83GF Score
Rohto Pharmaceutical Co Ltd TSE:4527
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rohto Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=384.592/112.7000*112.7000
=384.592

Current CPI (Mar. 2026) = 112.7000.

Rohto Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 144.314 98.100 165.792
201609 167.770 98.000 192.936
201612 175.091 98.400 200.536
201703 188.955 98.100 217.077
201706 156.921 98.500 179.543
201709 185.958 98.800 212.120
201712 199.148 99.400 225.795
201803 208.838 99.200 237.258
201806 177.619 99.200 201.791
201809 203.589 99.900 229.674
201812 207.480 99.700 234.534
201903 214.118 99.700 242.037
201906 182.921 99.800 206.565
201909 212.125 100.100 238.826
201912 208.253 100.500 233.533
202003 220.060 100.300 247.266
202006 169.451 99.900 191.162
202009 193.601 99.900 218.407
202012 203.738 99.300 231.231
202103 224.550 99.900 253.321
202106 184.978 99.500 209.518
202109 212.844 100.100 239.636
202112 231.624 100.100 260.779
202203 243.144 101.100 271.042
202206 228.424 101.800 252.882
202209 253.732 103.100 277.358
202212 288.240 104.100 312.052
202303 272.764 104.400 294.449
202306 267.363 105.200 286.424
202309 291.535 106.200 309.378
202312 320.370 106.800 338.068
202403 304.475 107.200 320.096
202406 298.825 108.200 311.253
202409 309.101 108.900 319.887
202412 379.436 110.700 386.291
202503 361.382 111.100 366.586
202506 362.730 111.700 365.977
202509 355.802 112.000 358.026
202512 380.394 113.000 379.384
202603 384.592 112.700 384.592

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円1,060.31 mean?
Rohto Pharmaceutical Co (TSE:4527) has a Cyclically Adjusted Revenue per Share of 円1,060.31 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Rohto Pharmaceutical Co and its competitors.
Is Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Rohto Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円1,060.31. Overall, Rohto Pharmaceutical Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to PG and CL?
Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share of 円1,060.31 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Consumer Packaged Goods company?
A good Cyclically Adjusted Revenue per Share depends on the Consumer Packaged Goods industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Rohto Pharmaceutical Co and its competitors. Rohto Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円1,060.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rohto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co (TSE:4527) is currently considered Modestly Undervalued. The stock's GF Value™ is 円3,479.27, compared to a current price of 円2,483.50 — trading 28.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円1,060.31. Rohto Pharmaceutical Co's overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Rohto Pharmaceutical Co (TSE:4527), the current Cyclically Adjusted Revenue per Share is 円1,060.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rohto Pharmaceutical Co (TSE:4527) Overvalued in 2026?

Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued. The current stock price of 円2,483.50 is trading 28.6% below its estimated GF Value™ of 円3,479.27. GuruFocus considers Rohto Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4527:

  • Cyclically Adjusted Revenue per Share: 円1,060.31
  • GF Value™: 円3,479.27 vs. price of 円2,483.50 (28.6% below fair value)
  • GF Score™: 83/100 with 2 warning signs

No single metric tells the full story. See the TSE:4527 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rohto Pharmaceutical Co Business Description

Other Exchanges RPHCF:USAUC1:Germany
Address 1-8-1 Tatsuminishi, Ikuno-ku, Osaka, JPN, 544-8666
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
83GF Score

Get the complete analysis for TSE:4527

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,483.50
Price
円3,479.27
GF Value